{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:52:59Z","timestamp":1778637179867,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jpba.2020.113250","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T14:08:01Z","timestamp":1584022081000},"page":"113250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS\/MS"],"prefix":"10.1016","volume":"185","author":[{"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"\u00c1lvarez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Ainara","family":"P\u00e9rez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Sanju\u00e1s-Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Sc\u00e9vola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Niub\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Videla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113250_bib0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.idc.2019.05.003","article-title":"Initial antiretroviral therapy in an integrase inhibitor era: can we do better?","volume":"33","author":"Kelly","year":"2019","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"10.1016\/j.jpba.2020.113250_bib0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000468","article-title":"Bictegravir","volume":"13","author":"Spagnuolo","year":"2018","journal-title":"Curr. Opin. HIV AIDS."},{"key":"10.1016\/j.jpba.2020.113250_bib0015","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113250_bib0020","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV."},{"key":"10.1016\/j.jpba.2020.113250_bib0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs."},{"issue":"2017","key":"10.1016\/j.jpba.2020.113250_bib0030","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV\u20101 infection (GS\u2010US\u2010380\u20101489): a double\u2010blind, multicentre, phase 3, randomised controlled non\u2010inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.jpba.2020.113250_bib0035","doi-asserted-by":"crossref","first-page":"e4379","DOI":"10.1002\/bmc.4379","article-title":"Development and validation of LC\u2013MS\/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study","volume":"33","author":"Prathipati","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2020.113250_bib0040","first-page":"441","article-title":"Bioanalytical method development and validation for simultaneous determination of bictegravir, tenofovir and emtricitabine in human plasma by LC-MS\/MS","volume":"7","author":"Raju","year":"2018","journal-title":"World J. Pharm. Pharmac. Sci."},{"key":"10.1016\/j.jpba.2020.113250_bib0045","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma","volume":"181","author":"Gougeta","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113250_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2012.11.018","article-title":"A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds","volume":"75","author":"Wang","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113250_bib0055","series-title":"Guideline on bioanalytical method validation","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.jpba.2020.113250_bib0060","series-title":"Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline (EP06-A)","author":"Clinical and Laboratory Standard Institute","year":"2003"},{"key":"10.1016\/j.jpba.2020.113250_bib0065","series-title":"Liquid Chromatography-mass spectrometry methods; approved guideline (CLSI C62-A)","author":"Clinical and Laboratory Standard Institute","year":"2014"},{"key":"10.1016\/j.jpba.2020.113250_bib0070","series-title":"International Federation of Clinical Chemistry and Laboratory Medicine, Mass spectrometry in the clinical laboratory: General principles and guidance; approved guideline (CLSI C50-A)","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"10.1016\/j.jpba.2020.113250_bib0075","doi-asserted-by":"crossref","unstructured":"J. Tiraboschi, A. Imaz, S. Khoo, J. Niubo, P. Prieto, M. Saumoy, S.D. Penchala, B. Garcia, C. Padilla, S. Videla, D. Podzamczer. Total and unbound bictegravir concentrations and viral suppression in CSF of HIV-infected patients (Spanish HIV\/AIDS Research Network, PreEC\/RIS 56). J. Infect. Dis. [In Press]. https:\/\/doi.org\/10.1093\/infdis\/jiz624.","DOI":"10.1093\/infdis\/jiz624"},{"key":"10.1016\/j.jpba.2020.113250_bib0080","first-page":"137","article-title":"Properties and units in the clinical laboratory sciences, Part XXIII, The NPU terminology, principles, and implementation: a user\u2019s guide (IUPAC Technical Report)","volume":"84","author":"Magdal","year":"2012","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.jpba.2020.113250_bib0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jpba.2020.113250_bib0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.drudis.2014.11.010","article-title":"Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines","volume":"20","author":"Illamola","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2020.113250_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/FTD.0b013e3181817318","article-title":"Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction","volume":"30","author":"Fayet","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2020.113250_bib0100","series-title":"Bioanalytical method validation\u2015Guidance for industry","author":"Food and Drug Administration","year":"2018"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520300170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520300170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:04:31Z","timestamp":1760000671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708520300170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":20,"alternative-id":["S0731708520300170"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113250","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113250"}}